Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in   docetaxel-pretreated patients (pts) with metastatic castrate-resistant   prostate cancer (mCRPC).

Titel:: Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Dokumenttyp:: Meeting Abstract
Autor(en):: Yu, Evan Y.; Massard, Christophe; Retz, Margitta; Tafreshi, Ali; Carles Galceran, Joan; Hammerer, Peter; Fong, Peter C. C.; Shore, Neal D.; Joshua, Anthony; Linch, Mark David; Gurney, Howard; Romano, Emanuela; Augustin, Marinela; Piulats, Josep M.; Wu, Haiyan; Schloss, Charles; Poehlein, Christian Heinrich; De Bono, Johann S.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2019
Band / Volume:: 37 Suppl S
Heft / Issue:: 7
Volltext / DOI:: doi:10.1200/JCO.2019.37.7_suppl.145
Print-ISSN:: 0732-183X
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: